Related Experiment Video
Updated: May 23, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[Metabolic disorders in patients with psoriasis]
Ewelina Sikora-Grabka1, Marcin Adamczak, Andrzej Wiecek
1Katedra i Klinika Nefrologii, Endokrynologii i Chorób Przemiany Materii, Slaski Uniwersytet Medyczny w Katowicach.
Przeglad Lekarski
|April 24, 2012
Summary
Psoriasis patients often have metabolic syndrome due to systemic inflammation. Lifestyle changes and medication can help manage psoriasis, metabolic syndrome, and reduce cardiovascular risk.
Area of Science:
- Dermatology and Immunology
- Cardiovascular Medicine
- Endocrinology
Context:
- Psoriasis is a chronic autoimmune skin disease characterized by systemic inflammation.
- Patients with psoriasis exhibit a higher incidence of metabolic syndrome.
- Chronic inflammation links psoriasis to metabolic syndrome components like obesity, dyslipidemia, hypertension, and diabetes.
Purpose:
- To explore the relationship between psoriasis, systemic inflammation, and metabolic syndrome.
- To understand the role of chronic inflammation and cytokines in comorbidities.
- To outline management strategies for psoriasis patients with metabolic syndrome.
Summary:
- Psoriasis involves systemic inflammation with elevated proinflammatory proteins (e.g., CRP, TNF-alpha).
- Metabolic syndrome components (impaired glucose tolerance, obesity, dyslipidemia, hypertension) are more common in psoriasis patients.
- Chronic inflammation is the likely link, with cytokines potentially driving atherosclerosis and insulin resistance.
Impact:
- Highlights the link between psoriasis and metabolic syndrome, emphasizing systemic inflammation.
- Suggests lifestyle modifications and pharmacotherapy are crucial for managing cardiovascular risk in these patients.
- Underscores the importance of addressing metabolic syndrome components to prevent complications like chronic kidney disease.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:21Overview of Protein Metabolism
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...